• Johnson & Johnson won FDA Priority Review for RYBREVANT FASPRO as a potential first-in-class subcutaneous EGFR/MET therapy in advanced head and neck cancer.
• The sBLA targets adults with recurrent or metastatic HNSCC whose disease progressed on platinum chemotherapy and PD-1/PD-L1 treatment; FDA decision expected in about six months.
• OrigAMI-4 data showed a 42% overall response rate for monotherapy, with more than one-third of responders achieving complete response.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607300830PR_NEWS_USPR_____NY11124) on July 30, 2026, and is solely responsible for the information contained therein.